MetrionAIIntelligence

Sign in Register

Home Watchlist Market News High Impact News Market Movers Screener Portfolio Calculators Heatmap Compare Calendars Crypto Forex Macro Maps

Research Tools

Financial Analysis Analyst Estimates Insider Trading Market Guide Trading Ideas Charts

Financial Analysis

Highlights Income Statement Balance Sheet Cash Flow Multiples Profitability

Loading market dashboard

My Watchlist

Sign in to track securities

Create an account to keep a persistent watchlist.

Home High Impact News Market Movers

Loading news article

Back to markets

fool.com/June 4, 2026 at 9:27 AMGLP

Eli Lilly Sees More Dealmaking Ahead as Management Looks To Leverage Its GLP-1 Success

Eli Lilly's GLP-1 drugs Mounjaro and Zepbound are seeing massive demand. Like all drugs, Mounjaro and Zepbound have time-limited patent protections.

Open original source